{"prompt": "['6.3.2 Advantage eClinical is programmed for automatic electronic distribution of SAE', 'reports to the following individuals: the AMC ODMC, AMC Medical Monitor,', 'Protocol Chairs, and the Principal Investigator at the institution.', '6.3.3 Expedited reporting guidelines', 'Investigators must report ALL SAEs (as defined in Section 6.2.3) that occur from', 'enrollment through 30 days following protocol treatment discontinuation to the', \"AMC and IRBs as required. The investigator's initial report to the AMC will be\", 'made using the Adverse Event form in Advantage eClinical within 24 hours of', 'awareness of the event, followed by a completed SAE form within the following', 'timelines.', 'Grade 3 SAEs: complete SAE form within 10 calendar days of investigator', 'awareness', 'Grade 4 or 5 SAEs: complete SAE form within 5 calendar days of investigator', 'awareness', 'After 30 days following treatment discontinuation, SAEs will only be reported in', 'the SAE form if determined by the investigator to have an attribution to treatment', 'of possible, probable, or definite.', 'Death due to progressive disease should be reported as Grade 5 \"General', 'disorders and administration site conditions - Disease Progression.\" Evidence', 'that the death was a manifestation of underlying disease (e.g., radiological changes', 'suggesting tumor growth or progression: clinical deterioration associated with a', 'disease process) should be submitted.', '6.3.4 Expedited reporting for pregnancy', 'Female participants who become pregnant or initiate breastfeeding while on', 'protocol treatment must immediately discontinue protocol treatment. Participants', 'will continue to be followed for the remainder of the study visit schedule and', 'procedures. AMC-S007 will not provide perinatal care for women. Women who', 'become pregnant will be referred to local clinics and/or other research studies for', 'prenatal and postpartum care.', 'Pregnancy reporting and outcomes will be documented by completion of the', 'appropriate CRFs, including the Adverse Event form, using the appropriate term in', 'the system organ class (SOC) for Pregnancy, puerperium and perinatal conditions.', '6.3.5 Expedited reporting to regulatory authorities', 'The principal investigator is responsible for ensuring that any AE or SAE that', 'requires reporting to its IRB or respective national regulatory authority is completed', 'in accordance with legal and regulatory timelines.', 'As this trial will not be conducted in the U.S., and will not support a marketing', 'application or change in labeling or advertising for the drug, the trial is exempt from', 'the requirement for an IND. No serious adverse event reporting to FDA is required.', '6.4', 'Routine Adverse Event Reporting', 'With the exception of the cases noted below, selected adverse events that occur within', 'AMC-S007 (Version 2.0) 20MAR2018', '29', 'NCI Version Date 20MAR2018']['timeframes defined in protocol Section 6.4.3 must be reported in routine study data', 'submissions.', '6.4.1 Additional protocol-specific routine adverse event reporting exclusions', 'All grade 1 adverse events are not required to be reported in the Adverse Event', 'Form in Advantage eClinical. These adverse events must be recorded in the source', 'documents only.', '6.4.2 Timeline for routine adverse event reporting', 'AEs will be recorded in the source and assessed for routine reporting requirements', 'from receipt of the first dose of BV through the treatment discontinuation', 'evaluation. Following treatment discontinuation, only SAEs that are possibly,', 'probably, or definitely attributed to treatment, or grade 5 SAEs will be reported in', 'the AE form.', '6.5', 'Secondary Malignancy', 'A secondary malignancy is a cancer caused by treatment for a previous malignancy (e.g.,', 'treatment with an agent/intervention, radiation, or chemotherapy). A secondary', 'malignancy is not considered a metastasis of the initial neoplasm.', 'All secondary malignancies that occur following treatment with standard treatment on this', 'protocol will be reported expeditiously via Advantage eClinical. Three options are', 'available to describe the event:', 'Leukemia secondary to oncology chemotherapy (e.g., acute myelocytic leukemia', '[AML])', 'Myelodysplastic syndrome (MDS)', 'Treatment-related secondary malignancy', 'Any malignancy possibly related to cancer treatment (including AML/MDS) should also', 'be reported via the routine reporting mechanisms outlined in each protocol.', '6.6', 'Second Malignancy', 'A second malignancy is one unrelated to the treatment of a prior malignancy (and is NOT', 'a metastasis from the initial malignancy). Second malignancies require ONLY routine', 'adverse event reporting.', 'AMC-S007 (Version 2.0) 20MAR2018', '30', 'NCI Version Date 20MAR2018']['7.0', 'PHARMACEUTICAL INFORMATION', 'No medications will be provided by the study. The site will source medications from its', 'usual commercial pharmacy per institutional policy, and administer these drugs in', 'accordance with the approved package inserts.', '7.1', 'Study Product Preparation', '7.1.1', 'Bleomycin', 'Description', 'Bleomycin is an antibiotic complex produced by fermentation from Streptomyces', 'verticillus. It causes single- and double-strand DNA breaks through formation of', 'an intermediate iron complex. DNA synthesis, and to a lesser degree, RNA and', 'protein synthesis are inhibited. Bleomycin is cell cycle phase-specific. Please refer', 'to the approved package insert for complete prescribing and toxicity information.', 'Reconstitution of Lyophilized Product', 'The locally-available formulations of bleomycin are packaged as 15 units of', 'bleomycin sulphate powder per vial. Instructions for reconstitution described for', \"the Zuvius Lifescience product should be followed: Zuvius's formulation of\", 'bleomycin is packaged as 15 units of bleomycin sulphate powder per vial. Using', 'aseptic technique, reconstitute each vial with 5 mL of 0.9% sodium chloride for', 'injection to yield 3 Units/mL (15 Units/ 5 mL) solution. If these reconstitution and', 'preparation instructions are not in accordance with the package insert of the locally-', 'sourced bleomycin, then the site should must the package insert and proposed', 'preparation instructions to the protocol team for review and approval prior to use.', \"Withdraw study participant's calculated dose of bleomycin in mL from the\", 'reconstituted bleomycin vial(s) into a syringe and inject it into a 50 mL 0.9%', 'sodium chloride for injection IV bag.', 'Administer the prepared bleomycin in 50 mL 0.9% sodium chloride for injection', 'IV bag by IV infusion over 10 minutes.', 'Bleomycin prepared in 50 mL 0.9% sodium chloride IV bag for infusion should be', 'stored as directed by the manufacturer in the package insert.', 'Do not use if a precipitate, foreign matter, or discoloration is present.', 'Bleomycin for injection should not be reconstituted or diluted with 5% dextrose for', 'injection or other dextrose-containing diluents, as loss of potency can occur.', 'Do not mix bleomycin with other drugs or solutions, as compatibility is unknown.', 'Caution should be exercised in handling bleomycin. The use of gloves and gown is', 'recommended. If bleomycin comes in contact with the skin or mucosa, immediately', 'wash thoroughly with soap and water.', 'Administration', 'Reconstitute with 5-10mL normal saline.', 'AMC-S007 (Version 2.0) 20MAR2018', '31', 'NCI Version Date 20MAR2018']", "completion": ""}